Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 27, 2026
TickeronGET DAILY SIGNALS
Universal Health Services (UHS) Delivers Q3 Revenue Growth of 5.3% but Margin Pressure Persists

Universal Health Services (UHS) Delivers Q3 Revenue Growth of 5.3% but Margin Pressure Persists

Key Takeaways

  • Net revenue increased 5.3% year over year to $4.73 billion, aligning closely with analyst expectations of roughly $4.71 billion.
  • Adjusted earnings per share reached $5.22, slightly above the consensus estimate of about $5.15 yet lower than the $5.69 recorded in the prior-year quarter.
  • Adjusted EBITDA totaled $624.6 million, below the anticipated $634.9 million.
  • The adjusted operating margin narrowed to 10.2%, a 1.4 percentage point decline from the year-ago period, even as same-store sales rose 4.7%.
  • Universal Health Services posted third-quarter net income of $308.7 million and bought back 1.35 million shares for approximately $242.1 million.

Why These Results Matter in Context

Universal Health Services operates as one of the largest providers of hospital and behavioral health services in the country. Its quarterly performance offers useful signals on labor expenses, patient volumes, and reimbursement dynamics affecting the broader sector. This third-quarter report followed a difficult second quarter marked by revenue outperformance alongside reduced full-year EPS guidance and the loss of licenses at two behavioral health facilities. With attention centered on whether margins in the behavioral health area were beginning to stabilize, the latest numbers provided an important check on the company’s handling of higher operating costs alongside continued revenue expansion.

The Quarter’s Reported Figures

Universal Health Services posted third-quarter 2026 net revenue of $4.73 billion, representing a 5.3% increase from the same period a year earlier and essentially matching the consensus estimate near $4.71 billion. Same-store sales advanced 4.7% year over year, an improvement over the 2% growth seen in the comparable quarter. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Adjusted EPS came in at $5.22, a modest beat versus the roughly $5.15 consensus but below the $5.69 from the prior year. Net income reached $308.7 million. Adjusted EBITDA stood at $624.6 million, missing the expected $634.9 million and equating to a 13.2% margin. Profitability faced ongoing headwinds, with the adjusted operating margin falling to 10.2%—down 1.4 percentage points year over year—and the reported operating margin declining to 9.6% from 11.6%. The results incorporated a net favorable pre-tax effect of about $21 million from Medicaid supplemental payments, offset in part by a $26 million unfavorable pre-tax charge related to higher reserves for self-insured claims.

How the Market Responded

The market reaction stayed relatively subdued. Shares finished the release day near $177.32 and showed little movement in early after-hours trading, consistent with a mixed quarter where a small EPS beat was tempered by the EBITDA shortfall and continued margin compression. The stock had risen about 5% over the preceding three months but remained down roughly 19% over the trailing 12 months, highlighting ongoing investor caution around cost pressures and the pace of recovery in behavioral health.

What to Watch Going Forward

Looking ahead, several areas deserve close attention. Management had previously guided to full-year 2026 net revenue in the range of $18.417 billion to $18.789 billion, adjusted EBITDA net of noncontrolling interests between $2.641 billion and $2.789 billion, and EPS between $22.64 and $24.52. A key focus remains whether the behavioral health segment can stabilize margins after the licensing issues and ongoing litigation. Labor costs, particularly salaries, wages, and benefits, continue to represent a major variable for profitability, and any sustained reduction in staffing expenses could aid margin improvement. Changes in Medicaid reimbursement also warrant monitoring, as the company noted their potential effect on annual results. Finally, capital allocation through the share repurchase program, with roughly $735.4 million still authorized, may influence per-share outcomes in coming quarters. From what I see, tracking these elements will be essential for assessing the company’s trajectory.

Insights from AI-Assisted Research

In preparing this review, I turned to Tickeron’s AI Screener to quickly surface comparable healthcare names and evaluate how UHS stacks up on technical and fundamental metrics. The tool allowed me to filter across the sector efficiently and confirm that the margin pressures observed here appear consistent with broader industry trends right now. This approach helped refine my perspective without replacing the core fundamental analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: UHS

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


UHS in downward trend: price dove below 50-day moving average on November 19, 2026

UHS moved below its 50-day moving average on November 19, 2026 date and that indicates a change from an upward trend to a downward trend. In 26 of 35 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 74%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for UHS moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In 23 of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at 52%.

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UHS as a result. In 61 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.

The Moving Average Convergence Divergence Histogram (MACD) for UHS turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 26 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 60%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where UHS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The 50-day moving average for UHS moved above the 200-day moving average on October 27, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +2.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where UHS advanced for three days, in 245 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

UHS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 225 of 298 cases where UHS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 45 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. UHS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.533) is normal, around the industry mean (204.532). P/E Ratio (7.893) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (1.197) is also within normal values, averaging (2.498). Dividend Yield (0.004) settles around the average of (0.153) among similar stocks. P/S Ratio (0.621) is also within normal values, averaging (2.688).

The Tickeron Profit vs. Risk Rating rating for this company is 64 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.

The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are DaVita (NYSE:DVA), Community Health Systems (NYSE:CYH), WW International Inc (NASDAQ:WW).

Industry description

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

Market Cap

The average market capitalization across the Hospital/Nursing Management Industry is 5.37B. The market cap for tickers in the group ranges from 20.9K to 107.17B. HCA holds the highest valuation in this group at 107.17B. The lowest valued company is NMMCF at 20.9K.

High and low price notable news

The average weekly price growth across all stocks in the Hospital/Nursing Management Industry was -12%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was 0%. CHE experienced the highest price growth at 0%, while NIVF experienced the biggest fall at -88%.

Volume

The average weekly volume growth across all stocks in the Hospital/Nursing Management Industry was 13%. For the same stocks of the Industry, the average monthly volume growth was 102% and the average quarterly volume growth was 58%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 49
Price Growth Rating: 59
SMR Rating: 66
Profit Risk Rating: 83
Seasonality Score: -4 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a healthcare management company, which owns and operates acute care hospitals, behavioral health centers, surgical hospitals, ambulatory surgery centers and radiation oncology centers

Industry HospitalNursingManagement

Industry
Hospital Or Nursing Management
Address
367 South Gulph Road, Universal Corporate Center
Phone
+1 610 768-3300
Employees
101500
Web
https://www.uhs.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.